Clinical utility of cytokeratins as tumor markers

Parry, 1999, Intermediate filaments: molecular architecture, assembly, dynamics and polymorphism, Q. Rev. Biophys., 32, 99, 10.1017/S0033583500003516 Kirfel, 2003, Keratins: a structural scaffold with emerging functions, Cell. Mol. Life Sci., 60, 56, 10.1007/s000180300004 Strelkov, 2003, Molecular architecture of intermediate filaments, BioEssays, 25, 243, 10.1002/bies.10246 Osborn, 1982, Intermediate filaments: cell-type specific markers in the differentiation and pathology, Cell, 31, 303, 10.1016/0092-8674(82)90122-2 Fuchs, 1994, Intermediate filaments: structure, dynamics, function and disease, Ann. Rev. Biochem., 63, 345, 10.1146/annurev.bi.63.070194.002021 Moll, 1982, The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells, Cell, 31, 11, 10.1016/0092-8674(82)90400-7 Hatzfeld, 1985, Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized filaments by homologous and heterologous recombinations of purified polypeptides, J. Cell Biol., 101, 1826, 10.1083/jcb.101.5.1826 Coulombe, 2002, “Hard” and “soft” principles defining the structure, function and regulation of keratin intermediate filaments, Curr. Opin. Cell Biol., 14, 110, 10.1016/S0955-0674(01)00301-5 Steinert, 1988, Molecular and cellular biology of intermediate filaments, Ann. Rev. Biochem., 57, 593, 10.1146/annurev.bi.57.070188.003113 Lane, 1990, Use of keratin antibodies in tumor diagnosis, Cancer Biol., 1, 2707 Chu, 2002, Keratin expression in human tissues and neoplasms, Histopathology, 40, 403, 10.1046/j.1365-2559.2002.01387.x Ku, 1995, Identification of mutational analysis of the glycosylation sites of human cytokeratin 18, J. Biol. Chem., 270, 11820, 10.1074/jbc.270.20.11820 Ku, 1994, Identification of major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization, J. Cell Biol., 127, 161, 10.1083/jcb.127.1.161 Rydlander, 1996, Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18, Eur. J. Biochem., 241, 309, 10.1111/j.1432-1033.1996.00309.x Petak, 2001, Shared pathways: death receptors and cytotoxic drugs in cancer therapy, Pathol. Oncol. Res., 7, 95, 10.1007/BF03032574 Fadeel, 2000, The most unkindest cut of all: on the multiple roles of mammalian caspases, Leukemia, 14, 1514, 10.1038/sj.leu.2401871 Ku, 2001, Effect of mutation and phosphorylation of type I keratins on their caspase-mediated degradation, J. Biol. Chem., 276, 26792, 10.1074/jbc.M103315200 Leers, 1999, Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis, J. Pathol., 187, 567, 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J Caulin, 1997, Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis, J. Biol. Chem., 138, 1379 Sheard, 2002, Release of cytokeratin-18 and-19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis, J. Cell. Biochem., 85, 670, 10.1002/jcb.10173 Stigbrand, 1998, Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 workshop, Tumor Biol., 19, 132, 10.1159/000029984 Nap, 2001, Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratins 8, 18 and 19, Tumor Biol., 22, 4, 10.1159/000030149 Gion, 2000, Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis, Breast Cancer Res. Treat., 59, 211, 10.1023/A:1006318112776 Lindman, 2000, Serum markers TPS, TPA and CA 15-3 as monitors of chemotherapy in patients with metastatic breast cancer, J. Tumor Marker Oncol., 15, 177 Plebani, 1995, Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improve the results?, Br. J. Cancer, 72, 170, 10.1038/bjc.1995.296 Bennink, 1999, Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radioimmunometric assay for the follow-up of bladder cancer, Anticancer Res., 19, 2609 Nicolini, 1995, Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the diagnosis of primary colateral cancer and its relapse, Cancer Detect. Prev., 19, 183 Rosati, 2000, Use of tumor markers in the management of head and neck cancer, Int. J. Biol. Markers, 15, 179, 10.1177/172460080001500209 Mellerick, 1990, On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18 and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum, Oncogene, 5, 1007 Bodenmüller, 1994, Lung cancer-associated keratin 19-fragment: development and biochemical characterization of the new serum assay Enzymun Test CYFRA 21-1, Int. J. Biol. Markers, 9, 75, 10.1177/172460089400900203 Nisman, 1998, Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in non small cell lung carcinoma: does the combined use of cytokeratin markers give an additional information?, Cancer, 10, 1850, 10.1002/(SICI)1097-0142(19980515)82:10<1850::AID-CNCR6>3.0.CO;2-R Yen, 1998, A study of the new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen, Clin. Otolaryngol., 23, 82, 10.1046/j.1365-2273.1998.00101.x Bonfrer, 1994, Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18, Tumor Biol., 15, 210, 10.1159/000217894 Einarsson, 1999, TPS: a cytokeratin serum tumor marker for effective therapy control of cancer patients with focus on breast cancer, J. Clin. Ligand Assay, 22, 348 van Dalen, 1996, Treatment response in metastatic breast cancer: a multicenter study comparing UICC criteria and tumor marker changes, Breast, 5, 82, 10.1016/S0960-9776(96)90126-5 van Dalen, 1998, The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. A multicenter study, Int. J. Biol. Markers, 13, 10, 10.1177/172460089801300103 Kramer, 1997, Serial tissue polypeptide specific antigen in the follow-up of hormone treated carcinoma of the prostate, J. Urol., 158, 1446, 10.1016/S0022-5347(01)64239-3 Polito, 1997, Serum markers for monitoring of prostatic carcinoma, Prostate, 33, 208, 10.1002/(SICI)1097-0045(19971101)33:3<208::AID-PROS10>3.0.CO;2-O Kil, 2003, Tissue polypeptide specific antigen (TPS) determination before and during intermittent maximal androgen blockade in patients with prostatic carcinoma, Eur. Urol., 43, 31, 10.1016/S0302-2838(02)00499-2 van Dalen, 2000, Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients, Gynecol. Oncol., 79, 444, 10.1006/gyno.2000.5982 Glimelius, 1996, Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements, Acta Oncol., 35, 141, 10.3109/02841869609098494 Berglund, 2002, Tumor markers as early predictors of response to chemotherapy in advanced colorectal carcinoma, Ann. Oncol., 13, 1430, 10.1093/annonc/mdf220 Bjorklund, 1996, TPS (tissue polypeptide specific antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer, Tumordiagn Ther., 17, 67 Giai, 1995, TPS and CA15-3 serum values as a guide for treating and monitoring breast cancer patients, Anticancer Res., 15, 2711 Barak, 1994, TPS in evaluation of response to Taxol and interferon therapy in breast cancer patients, J. Tumor Marker Oncol., 9, 89 Barak, 1997, TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons, J. Tumor Marker Oncol., 12, 17 Barak, 1995, Breast cancer detection by mammography, CA 15-3 and TPS, J. Tumor Marker Oncol., 10, 51 Barak, 1998, Clinical utility of TPS in breast cancer, Tumor Biol., 19, 59 Barak, 1998, TPS-prognosticator in breast cancer, Anticancer Res., 18, 4982 Findeisen, 1998, Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer, Clin. Chem. Lab. Med., 36, 841, 10.1515/CCLM.1998.148 Soletormos, 2000, Assessment of CA15-3, CEA and TPA concentrations during monitoring of breast cancer, Clin. Chem. Club Med., 38, 453, 10.1515/CCLM.2000.066 Nicolini, 1997, Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts, Int. J. Biol. Markers, 12, 181, 10.1177/172460089701200408 Nekulova, 1994, Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction, Neoplasma, 41, 113 Nicolini, 1991, Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients, Br. J. Cancer., 64, 154, 10.1038/bjc.1991.260 Barak, 1993, CA 125—The ovarian cancer tumor marker, Israeli Cancer J. Bamah, l7, 10 van Dalen, 1999, Prognostic significance of CA 125 and TPS levels after chemotherapy in ovarian cancer patients, Anticancer Res., 19, 2523 Chechlinska, 2003, The origin of cytokines, soluble cytokine receptors and CA125 in ascitic fluids and sera of ovarian cancer patients, Tumor Biol., 24, 76 Sedlaczek, 2002, Comparative analysis of CA125, Tissue Polypeptide Specific antigen, and soluble Interleukin-2 receptor alfa levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma, Cancer, 95, 1886, 10.1002/cncr.10917 Hording, 1990, CA 125, placental alkaline phosphatase, and tissue polypeptide antigen in the monitoring of ovarian carcinoma. A comparative study of three different tumor markers, Gynecol. Obstet. Invest., 30, 178, 10.1159/000293261 Tholander, 1990, Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease, Gynecol. Oncol., 39, 26, 10.1016/0090-8258(90)90394-Z Toftager-Larsen, 1992, CA-125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma, Gynecol. Obstet. Invest., 33, 177, 10.1159/000294876 Panza, 1988, Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma, Cancer, 61, 76, 10.1002/1097-0142(19880101)61:1<76::AID-CNCR2820610113>3.0.CO;2-G Hasholzner, 1994, Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma, Anticancer Res., 14, 2743 Tempfer, 1998, CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases, Br. J. Cancer, 78, 1108, 10.1038/bjc.1998.636 Duffy, 1998, CA 19-9 as a marker for gastrointestinal cancers: a review, Ann. Clin. Biochem., 35, 364, 10.1177/000456329803500304 Slesak, 2000, Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis, Cancer, 89, 83, 10.1002/1097-0142(20000701)89:1<83::AID-CNCR12>3.0.CO;2-J Leo, 1991, Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?, J. Urol., 145, 802, 10.1016/S0022-5347(17)38456-2 Banal, 2001, Comparison of Cyfra 21-1 and SCC assays in head and neck tumors, Tumor Biol., 22, 27, 10.1159/000030152 Molina, 1995, Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC, Anticancer Res., 15, 479 Sanislo, 2003, Predictive value of cytokeratin 18 fragments in patients with locally advanced head and neck tumors, Tumor Biol., 24, 80 Nagler, 1999, Early diagnosis and treatment monitoring roles of tumour markers Cyfra 21-1 and TPS in oral squamous cell carcinoma, Cancer, 85, 1018, 10.1002/(SICI)1097-0142(19990301)85:5<1018::AID-CNCR2>3.0.CO;2-R Pujol, 1993, Serum fragments of cytokeratin subunit 19 measured by Cyfra 21-1 immunoradiometric assay as a marker of lung cancer, Cancer Res., 53, 1 Buccheri, 1989, Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer, Chest, 93, 565, 10.1378/chest.93.3.565 Kulpa, 2002, Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients, Clin. Chem., 48, 1931, 10.1093/clinchem/48.11.1931 Nisman, 1998, Prognostic value of CEA, Cyfra 21-1 and TPS in different subtypes of lung cancer, Anticancer Res., 18, 4982 Devine, 1994, Serum markers CASA, CEA, CYFRA 21-1, MSA, NSE, TPA and TPS in lung cancer, Int. J. Oncol., 4, 1129 Pujol, 1996, Cytokeratins as serum markers in lung cancer: a comparison of Cyfra 21-1 and TPS, Am. J. Respir. Crit. Care Med., 154, 725, 10.1164/ajrccm.154.3.8810612 Ebert, 1998, Cyfra 21-1, TPS and NSE in the follow-up of non-small (NSCLC) and small cell lung cancer (SCLC), Anticancer Res., 18, 4983 Stieber, 1993, Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer, Eur. J. Clin. Chem. Clin. Biochem., 31, 689 Stieber, 1999, CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC), Anticancer Res., 19, 2665 Molina, 2003, Tumor markers (CEA, CA125, CYFRA21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognosis factors, Tumor Biol., 24, 209, 10.1159/000074432 Nisman, 1998, Cytokeratin markers in malignant pleural mesothelioma, Cancer Detect. Prev., 22, 416, 10.1046/j.1525-1500.1998.00053.x Correale, 1994, Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen, Int. J. Biol. Markers, 9, 231, 10.1177/172460089400900405 Mizushima, 1990, Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay, Oncology, 47, 43, 10.1159/000226783 Spinazzi, 1994, Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer, Cancer Detect. Prev., 18, 209 Buccheri, 1992, Prognostic value of the tissue polypeptide antigen in lung cancer, Chest, 101, 1287, 10.1378/chest.101.5.1287 Rapellino, 1994, Disappearance curves of tumor markers after radical surgery, Int. J. Biol. Markers, 9, 33, 10.1177/172460089400900107 Carpelan-Holmstrom, 1996, Independent prognostic value of preoperative serum markers CA242, tissue polypeptide antigen and human chronic gonadotrophin beta, but not of carcinoembryonic antigen of tissue polypeptide antigen in colorectal cancer, Br. J. Cancer, 74, 925, 10.1038/bjc.1996.458 von Kleist, 1996, Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon, Anticancer Res., 16, 2325 Maulard, 1994, Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study, Cancer, 73, 394, 10.1002/1097-0142(19940115)73:2<394::AID-CNCR2820730226>3.0.CO;2-Y Maulard-Durdux, 1997, Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study, J. Clin. Oncol., 15, 3446, 10.1200/JCO.1997.15.12.3446 Filella, 1996, TPA prognostic value in superficial bladder cancer, Anticancer Res., 16, 2173 Schmidt, 1992, Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy, Eur. Urol., 21, 10, 10.1159/000474879 van Poppel, 1996, Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer, Anticancer Res., 16, 205 Nisman, 2002, Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder cancer, Cancer, 94, 2914, 10.1002/cncr.10565 Senga, 1996, Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer, Urology, 48, 703, 10.1016/S0090-4295(96)00253-1 Sanchez-Carbayo, 1999, Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, and NMP22 to detect bladder cancer, J. Urol., 162, 1951, 10.1016/S0022-5347(05)68076-7 Yao, 1995, Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma, Anticancer Res., 15, 2819 Sánchez-Carbayo, 1999, Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder, J. Urol., 161, 1110, 10.1016/S0022-5347(01)61604-5 Sumi, 2000, Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder, Clin. Chim. Acta, 296, 111, 10.1016/S0009-8981(00)00208-4 Giannopoulos, 2001, Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors, J. Urol., 166, 470, 10.1016/S0022-5347(05)65965-4 Sánchez-Carbayo, 2001, Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer, J. Urol., 165, 1462, 10.1016/S0022-5347(05)66328-8 Sánchez-Carbayo, 2001, Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma, Cancer, 92, 2820, 10.1002/1097-0142(20011201)92:11<2820::AID-CNCR10092>3.0.CO;2-I